What the changes say
- Cronos restructured operations by exiting U.S. markets, ending Winnipeg fermentation, and scaling back Peace Naturals.
- Geopolitical instability in Israel and new Dutch market risks joined traditional regulatory hurdles.
- U.S. marijuana federal rescheduling efforts from Schedule I to Schedule III experienced procedural delays and executive orders.
What changed since the prior 10-K
New
- NewRisks Relating to Our Growth Strategy
There can be no assurance that recent operational and strategic initiatives will have a beneficial impact on our business, financial condition and results of operations. The timing, costs and benefits thereof cannot be guaranteed
Recent operational changes like exiting U.S. operations and ending Winnipeg fermentation may not achieve expected benefits or could disrupt our business.
- NewRisks Relating to Our Growth Strategy
economies of scale, invest more heavily in brand development, and respond more quickly to changing consumer preferences. As a result, our competitors may be more successful than us in gaining or maintaining market share
Competitors in the Canadian adult-use market may outpace us due to vertical integration with retailers.
- NewRisks Relating to Our Growth Strategy
PharmaCann Investment could be materially adversely affected. If we fail to realize the intended benefits of the PharmaCann Investment, or if market expectations regarding those benefits are not met, our stock price could decline
We have limited governance rights over PharmaCann and our investment may be diluted without our ability to influence decisions.
- NewRisks Relating to Operations in Israel
Conditions in Israel could materially and adversely affect our business, financial condition, and results of operations
Conditions in Israel could materially and adversely affect our business, financial condition, and results of operations.
- NewRisks Relating to Operations in Israel
We have operations in Israel through a strategic joint venture, Cronos Israel, including employees and management personnel based in Israel, and we are therefore exposed to risks associated with geopolitical instability and armed conflict in the region
The Middle East conflict and war involving Israel could disrupt our operations, employee safety, and import logistics into Israel.
- NewRisks Relating to Production and Distribution of Products
We have in the past and may in the future experience unauthorized access to our information technology systems or other cybersecurity incidents, which could disrupt our operations and have a material adverse effect on our business
We have experienced and may continue to experience cybersecurity incidents or cyberattacks affecting our IT and SaaS platforms.
- NewRisks Relating to Intellectual Property
making considerable investments in similar new and improved cannabis germplasm products. Consequently, there is no assurance that we will successfully develop new cannabis germplasm to the point of commercial viability in the markets we serve on a timely basis
We may fail to successfully develop new cannabis germplasm or maintain necessary third-party intellectual property licenses to commercial viability.
- NewRisks Relating to Entry into New Markets
Our expansion into the Netherlands exposes us to unique regulatory and commercial risks associated with the Dutch cannabis market
Our expansion into the Netherlands exposes us to regulatory and commercial risks under the Wietexperiment adult-use cannabis program.
- NewRisks Relating to Regulation and Compliance
The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex, evolving, and subject to significant uncertainty
Significant legal uncertainty surrounds the status of U.S. hemp and CBD under federal and state law.
Dropped
- DroppedRisks Relating to Our Growth Strategy
Moreover, as a result of changes in the nature of our operations at the Peace Naturals Campus, the continued operations of the Cronos GrowCo Facility has become more important to us. The Cronos GrowCo Facility is our principal source of raw materials
- DroppedRisks Relating to Our Growth Strategy
with obtaining approvals from or otherwise satisfying the requests of the state regulators or applicable laws, we may be required to divest all or a portion of the PharmaCann Option, or if after the exercise of the PharmaCann Option, our shares of PharmaCann
- DroppedRisks Relating to Our Growth Strategy
intangible assets exceed their fair value, the goodwill and other intangible assets are considered impaired, which would result in impairment losses and could have a material adverse effect on our consolidated financial position or results of operations
- DroppedRisks Relating to Operations in Israel
We have operations in Israel through a strategic joint venture, Cronos Israel
- DroppedRisks Relating to Operations in Israel
Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Any losses or damage incurred by us could have an adverse effect on our business, financial condition, and results of operations
- DroppedRisks Relating to Production and Distribution of Products
We may experience breaches of security at our facilities, which may expose us to the loss of inventory and risks related to violations of applicable laws and regulations
Reworded
- 91% rewrittenRisks Relating to Our Growth Strategy
We may not successfully execute or sustain our production capacity strategy
Updated production capacity strategy to reference the Kibbutz Gan Shmuel facility in Israel and Cronos GrowCo expansion completion.
Was: We may not successfully execute our production capacity strategy
- 88% rewrittenRisks Relating to Our Growth Strategy
We may not be able to successfully procure rare cannabinoids at commercially viable prices or in the quantities that we require
Clarified that following Winnipeg closure we now actively engage third-party suppliers to source rare cannabinoids for our products.
- 85% rewrittenRisks Relating to Our Growth Strategy
We may be unsuccessful in competing in the legal adult-use cannabis market in Canada
Truncated the discussion regarding competitor advantages in the Canadian adult-use legal cannabis market.
- 85% rewrittenRisks Relating to Regulation and Compliance
Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on our business
Added specific updates on the DEA Schedule III rescheduling process, administrative law judge retirement, and December 2025 Presidential Executive Order.
- 79% rewrittenRisks Relating to Production and Distribution of Products
We rely on third-party distributors and manufacturers to distribute and manufacture certain of our products, and those distributors and manufacturers may not perform their obligations
Added potential product liability, reputational damage, and improper storage risks stemming from third-party distributor and manufacturer failures.
- 78% rewrittenRisks Relating to Operations in Israel
The imposition of an anti-dumping duty on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations
Provided final outcomes regarding the Israeli anti-dumping duty on Canadian cannabis, noting the Ministry of Finance veto and Ministry of Justice memorandum.
- 78% rewrittenRisks Relating to Our Products
Our business may be impacted by conditions in the global economy and financial markets, including changes in inflation, interest rates, trade policy and overall economic conditions
Expanded macroeconomic factors to note that inflation may reduce consumer discretionary spending and added interest rate impacts on cash investments.
Was: Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates, trade policy and overall economic conditions
- 77% rewrittenRisks Relating to Our Growth Strategy
There can be no assurance that our current and future strategic alliances or expansions of existing relationships will have a beneficial impact on our business, financial condition and results of operations
Retained strategic alliance risk factors with minor stylistic updates to language regarding partner availability and integration costs.
Was: There can be no assurance that our current and future strategic alliances or expansions of scope of existing relationships will have a beneficial impact on our business, financial condition and results of operations
- 76% rewrittenRisks Relating to Our Growth Strategy
Our acquisition strategy may not be successful, and we have in the past, and may in the future, need to write down goodwill and intangible assets recognized upon acquisition
Was: Our acquisition strategy may not be successful, and we have in the past, and may in the future, need to write down the goodwill and indefinite-lived intangible assets recognized upon the acquisitions
- 72% rewrittenRisks Relating to Our Common Shares
We may require additional capital or issue additional securities in the future or be required to issue common shares pursuant to certain of our agreements, which may dilute holders of our securities
Was: We may require additional capital in the future or be required to issue common shares pursuant to certain of our agreements, which may dilute holders of our securities
- 66% rewrittenRisks Relating to Our Growth Strategy
We are subject to disabilities as a result of our settlement with the SEC that may expose us to increased future litigation and adversely affect our ability to raise capital
- 66% rewrittenRisks Relating to Production and Distribution of Products
Our cannabis cultivation operations are subject to risks inherent in an agricultural business
- 65% rewrittenRisks Relating to Our Growth Strategy
The industries and markets in which we operate are relatively new and may not continue to exist or grow as anticipated, and we may ultimately be unable to succeed in these industries and markets
Was: The industries and markets in which we operate are relatively new, and these industries and markets may not continue to exist or grow as anticipated or we may ultimately be unable to succeed in these industries and markets
- 65% rewrittenRisks Relating to Regulation and Compliance
Our ability to grow, process, store and sell cannabis in Israel is dependent on maintaining our cannabis cultivation, production and distribution licenses and our ability to export products to, or import products from, Cronos Israel is also dependent on obtaining the relevant permits
- 61% rewrittenRisks Relating to Intellectual Property
We may be unable to protect our inventions, trade secrets, and other intellectual property from discovery or unauthorized use or disclosure
Was: We may be unable to protect our inventions, trade secrets, and other intellectual property from discovery or unauthorized use
- 60% rewrittenRisks Relating to Our Growth Strategy
We may not be able to successfully manage changes in our business or sustain our growth
Was: We may not be able to successfully manage our growth
- 59% rewrittenRisks Relating to Our Growth Strategy
We rely largely on our own market research to forecast sales and market demand and market prices may differ from our forecasts
- 56% rewrittenRisks Relating to Our Growth Strategy
We have been, and may in the future be, required to write down intangible assets, including goodwill, due to impairment, which could have a material adverse effect on our results of operations or financial position
- 51% rewrittenRisks Relating to Our Products
Our products have in the past and may in the future be subject to recalls
- 51% rewrittenRisks Relating to Our Growth Strategy
We could have difficulty integrating the operations of businesses that we have acquired and will acquire
- 50% rewrittenRisks Relating to Competition
We may be unable to attract or retain skilled labor and personnel with experience in the cannabis sector and may be unable to attract, develop and retain additional employees required for our operations and future developments
Was: We may be unable to attract or retain employees with sufficient experience in the cannabis industry, and may prove unable to attract, develop and retain additional employees required for our development and future success
- 49% rewrittenRisks Relating to Our Growth Strategy
We may not be able to achieve or maintain profitability and may continue to incur losses in the future
- 48% rewrittenRisks Relating to Our Growth Strategy
Our U.S. strategy in part depends on the success of the PharmaCann Investment and there is no guarantee that we will exercise the PharmaCann Option in the near term, or at all, and, even if exercised, that the PharmaCann Investment will achieve the expected benefits of the PharmaCann Investment
Was: Our U.S. strategy in part depends on the success of the PharmaCann Investment and there is no guarantee that we will exercise the PharmaCann Option in the near term, or at all, and, even if exercised, that the PharmaCann Investment will achieve the expected benefits of the transaction
- 47% rewrittenRisks Relating to Intellectual Property
We may be subject to allegations that we are in violation of third-party intellectual property rights, and we may be found to infringe third-party intellectual property rights, possibly without the ability to obtain licenses necessary to use such third-party intellectual property rights
- 47% rewrittenRisks Relating to Our Products
We rely on third-party testing and analytical methods which are validated but have not yet been standardized
- 46% rewrittenRisks Relating to Our Growth Strategy
We may be unable to obtain adequate supplies of raw materials in a timely manner and at commercially reasonable prices
Was: We are anticipating further shortages in raw materials and may be unable to obtain adequate supplies of raw materials in a timely manner and at commercially reasonable prices
- 46% rewrittenRisks Relating to Our Growth Strategy
Wholesale price volatility could have a material adverse effect on our business
- 44% rewrittenRisks Relating to Our Products
We may be subject to litigation in the ordinary course of our marketing, distribution and sale of our products
- 40% rewrittenRisks Relating to Our Growth Strategy
We may not be able to supply the purchasers in various provinces and territories of Canada with our products in the quantities or prices anticipated, or at all, due to the discretion such purchasers have over purchasing, pricing, and product listings
Was: We may not be able to supply the purchasers in various provinces and territories of Canada with our products in the quantities or prices anticipated, or at all
- 39% rewrittenRisks Relating to Production and Distribution of Products
Any actual or perceived failure by us to comply with laws, regulations or any other obligations relating to privacy, data protection or the protection or transfer of personal data, could adversely affect our business
- 38% rewrittenRisks Relating to Our Growth Strategy
Termination or non-renewal of the Cronos GrowCo Supply Agreement could have a material negative impact on our ability to obtain cannabis biomass at commercially viable prices
- 34% rewrittenRisks Relating to Regulation and Compliance
We are constrained by law in our ability to market and advertise our products
- 33% rewrittenRisks Relating to Our Products
The Canadian excise duty framework may adversely affect our profitability
- 33% rewrittenRisks Relating to Our Products
We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer perception
- 30% rewrittenRisks Relating to Intellectual Property
The technologies, processes and formulations we use may face competition or become obsolete
- 27% rewrittenRisks Relating to Our Products
The controversy surrounding vaporizers and vaporizer products may materially and adversely affect the market for vaporizer products and expose us to litigation and additional regulation
- 26% rewrittenRisks Relating to Our Growth Strategy
The adult-use cannabis market in Canada has in the past been and may in the future become oversupplied
- 26% rewrittenRisks Relating to Our Growth Strategy
We are subject to liability arising from any fraudulent or illegal activity by our employees, contractors, manufacturers and consultants
- 24% rewrittenRisks Relating to Intellectual Property
Our intellectual property rights may be invalid or unenforceable under applicable laws, and we may be unable to have issued or registered, and unable to enforce, our intellectual property rights
- 22% rewrittenRisks Relating to Our Growth Strategy
There can be no assurance of continued growth in Israel and our performance in Israel depends on, among other things, our ability to continue to import cannabis into Israel and our joint venture partners
- 20% rewrittenRisks Relating to Our Common Shares
A substantial number of our securities are owned by a limited number of existing shareholders
All 90 risk factors
Headings as the filing states them, in filing order.
Risks Relating to Our Growth Strategy
- 01We have a limited operating history and therefore we are subject to many of the risks common to early-stage enterprises
- 02We may not be able to achieve or maintain profitability and may continue to incur losses in the future49% rewritten
- 03We may not be able to successfully manage changes in our business or sustain our growth60% rewritten
- 04Our use of joint ventures exposes us to risks associated with jointly owned investments
- 05There can be no assurance of continued growth in Israel and our performance in Israel depends on, among other things, our ability to continue to import cannabis into Israel and our joint venture partners22% rewritten
- 06Our acquisition strategy may not be successful, and we have in the past, and may in the future, need to write down goodwill and intangible assets recognized upon acquisition76% rewritten
- 07We are subject to disabilities as a result of our settlement with the SEC that may expose us to increased future litigation and adversely affect our ability to raise capital66% rewritten
- 08There can be no assurance that our current and future strategic alliances or expansions of existing relationships will have a beneficial impact on our business, financial condition and results of operations77% rewritten
- 09Wholesale price volatility could have a material adverse effect on our business46% rewritten
- 10We may be unable to obtain adequate supplies of raw materials in a timely manner and at commercially reasonable prices46% rewritten
- 11Our option to purchase a significant portion of Cronos GrowCo’s production could strain Cronos GrowCo’s ability to develop, maintain and grow profitable relationships with third-party customers
- 12Termination or non-renewal of the Cronos GrowCo Supply Agreement could have a material negative impact on our ability to obtain cannabis biomass at commercially viable prices38% rewritten
- 13We may not successfully execute or sustain our production capacity strategy91% rewritten
- 14We may not be able to successfully procure rare cannabinoids at commercially viable prices or in the quantities that we require88% rewritten
- 15There can be no assurance that recent operational and strategic initiatives will have a beneficial impact on our business, financial condition and results of operations. The timing, costs and benefits thereof cannot be guaranteedNew
- 16The industries and markets in which we operate are relatively new and may not continue to exist or grow as anticipated, and we may ultimately be unable to succeed in these industries and markets65% rewritten
- 17We may not be able to supply the purchasers in various provinces and territories of Canada with our products in the quantities or prices anticipated, or at all, due to the discretion such purchasers have over purchasing, pricing, and product listings40% rewritten
- 18The adult-use cannabis market in Canada has in the past been and may in the future become oversupplied26% rewritten
- 19We may be unsuccessful in competing in the legal adult-use cannabis market in Canada85% rewritten
- 20economies of scale, invest more heavily in brand development, and respond more quickly to changing consumer preferences. As a result, our competitors may be more successful than us in gaining or maintaining market shareNew
- 21We are subject to liability arising from any fraudulent or illegal activity by our employees, contractors, manufacturers and consultants26% rewritten
- 22Some jurisdictions may never develop markets for cannabis
- 23Our U.S. strategy in part depends on the success of the PharmaCann Investment and there is no guarantee that we will exercise the PharmaCann Option in the near term, or at all, and, even if exercised, that the PharmaCann Investment will achieve the expected benefits of the PharmaCann Investment48% rewritten
- 24PharmaCann Investment could be materially adversely affected. If we fail to realize the intended benefits of the PharmaCann Investment, or if market expectations regarding those benefits are not met, our stock price could declineNew
- 25We rely largely on our own market research to forecast sales and market demand and market prices may differ from our forecasts59% rewritten
- 26We could have difficulty integrating the operations of businesses that we have acquired and will acquire51% rewritten
- 27We have been, and may in the future be, required to write down intangible assets, including goodwill, due to impairment, which could have a material adverse effect on our results of operations or financial position56% rewritten
Risks Relating to Operations in Israel
- 28Conditions in Israel could materially and adversely affect our business, financial condition, and results of operationsNew
- 29We have operations in Israel through a strategic joint venture, Cronos Israel, including employees and management personnel based in Israel, and we are therefore exposed to risks associated with geopolitical instability and armed conflict in the regionNew
- 30Our operations may be disrupted by the obligations of personnel to perform military service
- 31The imposition of an anti-dumping duty on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations78% rewritten
Risks Relating to Our Products
- 32Clinical trials of cannabis-based medical products and treatments have a limited history, and any trials may not result in commercially viable products and treatments
- 33The controversy surrounding vaporizers and vaporizer products may materially and adversely affect the market for vaporizer products and expose us to litigation and additional regulation27% rewritten
- 34Future research may lead to findings that vaporizers, electronic cigarettes and related products are not safe for their intended use
- 35We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer perception33% rewritten
- 36We may be subject to litigation in the ordinary course of our marketing, distribution and sale of our products44% rewritten
- 37We may be subject to product liability claims
- 38Our products have in the past and may in the future be subject to recalls51% rewritten
- 39We rely on third-party testing and analytical methods which are validated but have not yet been standardized47% rewritten
- 40We may not be able to successfully develop new products or find a market for their sale
- 41The Canadian excise duty framework may adversely affect our profitability33% rewritten
- 42Our business may be impacted by conditions in the global economy and financial markets, including changes in inflation, interest rates, trade policy and overall economic conditions78% rewritten
Risks Relating to Production and Distribution of Products
- 43Our production facilities, and those of our strategic joint ventures, are integral to our operations, and any adverse changes or developments affecting such facilities may impact our business, financial condition and results of operations
- 44We have in the past and may in the future experience unauthorized access to our information technology systems or other cybersecurity incidents, which could disrupt our operations and have a material adverse effect on our businessNew
- 45Any actual or perceived failure by us to comply with laws, regulations or any other obligations relating to privacy, data protection or the protection or transfer of personal data, could adversely affect our business39% rewritten
- 46Our cannabis cultivation operations are subject to risks inherent in an agricultural business66% rewritten
- 47The inability of our suppliers to meet their financial or contractual obligations to us may result in disruption to our supply chain and could result in financial losses
- 48We rely on third-party distributors and manufacturers to distribute and manufacture certain of our products, and those distributors and manufacturers may not perform their obligations79% rewritten
Risks Relating to Intellectual Property
- 49We are subject to risks related to the protection and enforcement of our intellectual property rights, and we may be unable to protect or enforce our intellectual property rights
- 50We may be unable to protect our inventions, trade secrets, and other intellectual property from discovery or unauthorized use or disclosure61% rewritten
- 51Our intellectual property rights may be invalid or unenforceable under applicable laws, and we may be unable to have issued or registered, and unable to enforce, our intellectual property rights24% rewritten
- 52We may be subject to allegations that we are in violation of third-party intellectual property rights, and we may be found to infringe third-party intellectual property rights, possibly without the ability to obtain licenses necessary to use such third-party intellectual property rights47% rewritten
- 53making considerable investments in similar new and improved cannabis germplasm products. Consequently, there is no assurance that we will successfully develop new cannabis germplasm to the point of commercial viability in the markets we serve on a timely basisNew
- 54The technologies, processes and formulations we use may face competition or become obsolete30% rewritten
Risks Relating to Entry into New Markets
- 55Entering into new jurisdictions is inherently risky, may not be successful and could be costly
- 56Our expansion into the Netherlands exposes us to unique regulatory and commercial risks associated with the Dutch cannabis marketNew
- 57Controlled substance and other legislation and treaties may restrict or limit our ability to research, manufacture and develop a commercial market for our products outside of the jurisdictions in which we currently operate, and our expansion into such jurisdictions is subject to risks
- 58Investments and joint ventures outside of Canada are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal, regulatory and economic risk
Risks Relating to Regulation and Compliance
- 59We operate in highly regulated sectors where the regulatory environment is rapidly developing, and we may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business
- 60Our ability to grow, process, store and sell cannabis in Israel is dependent on maintaining our cannabis cultivation, production and distribution licenses and our ability to export products to, or import products from, Cronos Israel is also dependent on obtaining the relevant permits65% rewritten
- 61Changes in the laws, regulations and guidelines governing cannabis may adversely impact our business
- 62Our common shares are listed on the TSX and Nasdaq. We must comply with the TSX and Nasdaq requirements or guidelines when conducting business
- 63We are constrained by law in our ability to market and advertise our products34% rewritten
- 64Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on our business85% rewritten
- 65The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex, evolving, and subject to significant uncertaintyNew
Risks Relating to Competition
- 66The markets in which we operate are increasingly competitive, and we may compete for market share with other companies, both domestically and internationally, that may have longer operating histories and more financial resources, manufacturing, distribution, and marketing experience than us
- 67We face competition from the illegal cannabis market
- 68Regulatory non-compliance by licensed cannabis competitors may have an adverse effect on our business, results of operations and financial condition
- 69We have been and may in the future be required to write down inventory due to downward pressure on market prices, which could have a material adverse effect on our results of operations or financial position
- 70We may be unable to attract or retain skilled labor and personnel with experience in the cannabis sector and may be unable to attract, develop and retain additional employees required for our operations and future developments50% rewritten
Risks Relating to the Altria Investment
- 71Altria has significant influence over us following closing of the Altria Investment
- 72We have discretion in the use of net proceeds from the Altria Investment and may not use them effectively
- 73We may not realize the benefits of our strategic partnership with Altria, which could have an adverse effect on our business, financial condition and results of operations
- 74Altria’s significant interest in us may impact the liquidity of our common shares
- 75Future sales of our common shares by Altria could cause the market price for our common shares to fall
- 76Conflicts of interest may arise between us and our directors and officers, including as a result of the continuing involvement of certain of our directors with Altria and its affiliates
Risks Relating to Our Common Shares
- 77It is not anticipated that any dividend will be paid to holders of our common shares in the foreseeable future
- 78The market price for our common shares has in the past been volatile and may continue to be volatile and subject to significant fluctuation
- 79We may require additional capital or issue additional securities in the future or be required to issue common shares pursuant to certain of our agreements, which may dilute holders of our securities72% rewritten
- 80A substantial number of our securities are owned by a limited number of existing shareholders20% rewritten
- 81Investors in the U.S. may have difficulty bringing actions and enforcing judgments against us and others based on securities law civil liability provisions
- 82If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline
- 83We are dependent on our senior management
- 84We may be unable to obtain insurance coverage at acceptable rates and there may be coverage limitations and other exclusions which may not be sufficient to cover our potential liabilities
- 85Tax and accounting requirements may be interpreted or changed in ways that are complex and not necessarily anticipated by us, and we may face difficulty or be unable to implement and/or comply with any such interpretations or changes
- 86Natural disasters, unusual weather, pandemic outbreaks, boycotts and geopolitical events or acts of terrorism could adversely affect our operations and financial results
- 87Our business faces evolving and diverging expectations, requirements and demands from regulators, investors and other stakeholders, including with respect to environmental, social, governance and sustainability matters, which could expose us to numerous risks
- 88Climate change may disrupt our business and our efforts to address concerns relating to climate change could result in damage to our reputation
- 89Our financial performance is subject to risks of foreign exchange rate fluctuation, which could result in foreign exchange losses
- 90Our business, financial condition, results of operations and cash flows could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine
Other Cronos Group 10-Ks
- FY2024 10-K risk factors87 risks
Cronos Group faces risks primarily driven by early-stage operations, market uncertainties in Israel, raw material dependency on Cronos GrowCo, and regulatory hurdles in the cannabis sector.
Filed Feb 27, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.